

Potent Acetylcholinesterase Selective and Reversible Homodimeric Agent based on Tacrine for Theranostics

Virendra Kumar Meena^{a,b}, Shubhra Chaturvedi^a, Rakesh Kumar Sharma^b, Anil Kumar Mishra^a and Puja Panwar Hazari^{a,*}

^aDivision of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Brig S.K. Mazumdar Road, Delhi-110054, India.

^bDepartment of Chemistry, University of Delhi, Delhi-110007, India

Fig S1. ¹ H NMR spectrum of 9-Chloro-1,2,3,4-tetrahydroacridine (1).	S2
Fig S2. ¹³ C NMR spectrum of 9-Chloro-1,2,3,4-tetrahydroacridine (1).	S2
Fig S3. LC-MS mass spectrum of 9-Chloro-1,2,3,4-tetrahydroacridine (1).	S3
Fig S4. ¹ H NMR spectrum of N ¹ -(1,2,3,4-tetrahydroacridin-9-yl)ethane-1,2-diamine (2).	S4
Fig S5. ¹³ C NMR spectrum of N ¹ -(1,2,3,4-tetrahydroacridin-9-yl)ethane-1,2-diamine (2).	S5
Fig S6. LC-MS spectrum of N ¹ -(1,2,3,4-tetrahydroacridin-9-yl)ethane-1,2-diamine (2).	S5
Fig S7. ¹ H NMR spectrum of 5-amino-N ¹ ,N ³ -bis(2-(1,2,3,4-tetrahydroacridin-9-ylamino)ethyl)isophthalamide (4).	S6
Fig S8. ¹³ C NMR Spectrum of 5-amino-N ¹ ,N ³ -bis(2-(1,2,3,4-tetrahydroacridin-9-ylamino)ethyl)isophthalamide (4).	S6
Fig S9. LC-MS spectrum of 5-amino-N ¹ ,N ³ -bis(2-(1,2,3,4-tetrahydroacridin-9-ylamino)ethyl)isophthalamide (4).	S7
Fig S10. HR-MS spectrum of 5-amino-N ¹ ,N ³ -bis(2-(1,2,3,4-tetrahydroacridin-9-ylamino)ethyl)isophthalamide (4).	S7
Fig S11. Enzyme kinetic curves (Michaelis-Menton curve) of compound (4) on AChE and BuChE.	S8
Fig S12 Molecular docking analysis of various reference THA derivatives with compound (4).	S8

Fig S1.¹H NMR spectrum of 9-Chloro-1,2,3,4-tetrahydroacridine (**1**).




Fig S2.¹³C NMR spectrum of 9-Chloro-1,2,3,4-tetrahydroacridine (**1**).




Fig S3. LC-MS mass spectrum of 9-Chloro-1,2,3,4-tetrahydroacridine (**1**).




Fig S4.¹H NMR spectrum of N¹-(1,2,3,4-tetrahydroacridin-9-yl)ethane-1,2-diamine (**2**).




Fig S5. ^{13}C NMR spectrum of N^1 -(1,2,3,4-tetrahydroacridin-9-yl)ethane-1,2-diamine (**2**).




Fig S6. LC-MS spectrum of N^1 -(1,2,3,4-tetrahydroacridin-9-yl)ethane-1,2-diamine (**2**).




Fig S7. ^1H NMR spectrum of 5-amino-N¹,N³-bis(2-(1,2,3,4-tetrahydroacridin-9-ylamino)ethyl)isophthalamide(**4**) .




Fig S8. ^{13}C NMR Spectrum of 5-amino-N¹,N³-bis(2-(1,2,3,4-tetrahydroacridin-9-ylamino)ethyl)isophthalamide (**4**) .




Fig S9. LC-MS spectrum of 5-amino-N¹,N³-bis(2-(1,2,3,4-tetrahydroacridin-9-ylamino)ethyl)isophthalamide (**4**)




Fig S10. HR-MS spectrum of 5-amino-N¹,N³-bis(2-(1,2,3,4-tetrahydroacridin-9-ylamino)ethyl)isophthalamide (**4**)




Fig S11. Enzyme kinetic curves (Michaelis-Menton curve) of compound (4) on AChE (a) and BuChE (b).




Fig S12. Molecular docking analysis of various reference THA derivatives with compound 4.

Compound	Structure	Docking Score	Glide Score
Bis(7)-tacrine		19.897	19.897
11b		17.488	17.489
Compound (4)		20.746	20.747

In molecular docking analysis, docking and glide score were calculated in percentage with respect to bis(7)-tacrine by using the below formula:

$$\% \text{ docking score/Glide score W.R.T. bis(7)-tacrine} =$$

$$[\text{Docking/Glide Score of Inhibitor} - \text{Docking/Glide Score of bis(7)-tacrine}] / [\text{Docking/Glide Score of bis(7)-tacrine}] \times 100$$